SUBSCRIBE
SUBSCRIBE
News   FDA

Aventis Pharma Obtains Additional Approval for Taxoid Antitumor Agent TAXOTERE Injection

October 19, 2005 | 
1 min read
Tokyo (JCN) - Aventis Pharma of the sanofi-aventis Group announced on August 19 that it has obtained additional approval for TAXOTERE Injection, its proprietary taxoid antitumor agent, from the Ministry of Health, Labor and Welfare as of August 18.
FDA Approvals
Sanofi Sanofi
MORE ON THIS TOPIC
Document checking, agreement or contract validation, financial or budget analysis, search for document files concept, businessman manager holding big magnifying glass checking document paper.
FDA
Replimune’s melanoma drug would have been rejected again if not for senior CBER official
September 3, 2026
 · 
2 min read
 · 
Tristan Manalac
Huntington’s disease
UniQure files for FDA, UK approval of first gene therapy for Huntington’s disease
September 2, 2026
 · 
3 min read
 · 
Heather McKenzie
FDA
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
September 2, 2026
 · 
2 min read
 · 
Jef Akst
Business man jumping over barriers
Approvals
Takeda, Protagonist score broad FDA nod in rare blood cancer, setting up $2B opportunity
August 31, 2026
 · 
2 min read
 · 
Tristan Manalac